.png){kind=icon}
返回
N
Norikazu Masuda
kyoto university
64H指数
696论文数
3.0W被引数
收录论文 260
发表时间
.png){kind=icon}
Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD甲磺酸艾瑞布林与多西他赛或紫杉醇联合曲妥珠单抗和帕妥珠单抗作为HER2阳性局部晚期或转移性乳腺癌的一线治疗的疗效和安全性：JBCRG-M06/EMERALD研究的更新亚组分析.png)
PREAI
.png){kind=icon}
分享.png){kind=icon}
收藏Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)随机化、多中心II期研究：贝伐珠单抗和紫杉醇诱导后使用阿替利珠单抗和nab-紫杉醇治疗PD-L1阳性转移性三阴性乳腺癌患者的方案（INDUCE试验[JBCRG-M10]）.png)
BMJ Open
BMJ OpenIF2.3
PREAI
分享收藏Correction: Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2− advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study)更正: 日本HR /HER2 − 晚期乳腺癌患者一线或二线接受palbociclib联合内分泌治疗的总生存率: 一项多中心观察性研究 (p-bridge研究)Breast Cancer
OAAI
Breast CancerIF2.9
OAAI分享收藏Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02Tucatinib和trastuzumab emtansine用于既往治疗过的HER2阳性局部晚期和转移性乳腺癌患者：随机III期试验HER2CLIMB-02的主要分析Annals of OncologyOAAI
Annals of OncologyIF65.4
OAAI分享收藏Health-related quality of life and physical activity collected via mobile application and wearable device in patients with HR +/HER2 − advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone: 6-month longitudinal study (JBCRG-26)通过移动应用程序和可穿戴设备收集的HR+/HER2−晚期乳腺癌患者接受帕博西利比联合内分泌治疗或单纯内分泌治疗后的健康相关生活质量与身体活动：6个月纵向研究（JBCRG-26）Breast Cancer
OAAI
Breast CancerIF2.9
OAAI分享收藏Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor–positive, HER2‑negative advanced or metastatic breast cancer更正：来自日本的真实世界证据显示，在接受CDK4/6抑制剂联合内分泌疗法作为一线或二线治疗激素受体阳性、HER2阴性晚期或转移性乳腺癌患者的生存结局及治疗顺序方面的数据。Breast CancerOAAI
Breast CancerIF2.9
OAAI分享收藏Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer来自日本的真实世界证据，关于接受CDK4/6抑制剂联合内分泌治疗作为激素受体阳性、HER2阴性晚期或转移性乳腺癌的一线或二线治疗患者的生存结局及治疗顺序。BREAST CANCEROAAI
BREAST CANCERIF2.9
OAAI分享收藏